Xenon Pharmaceuticals Stock Earnings Reports

Xenon reported a highly productive quarter driven by positive Phase III X-TOLE2 results for azetukalner (AZK) in focal onset seizures that exceeded expectations and reinforced prior Phase II findings (rapid onset, dose-dependent responder rates, strong safety). The company plans an NDA submission in Q3 2026 and expects a standard FDA review plus DEA scheduling, targeting a launch in late 2027 or early 2028. Long-term open-label (48-month) data show sustained efficacy and meaningful seizure-freedom rates (approaching ~40% seizure-free ≥12 months in patients treated ≥48 months), which management says supports AZK’s potential to become a preferred anti-seizure medicine, especially among general neurologists given no titration, once-daily dosing and limited drug–drug interactions. Xenon is also enrolling three Phase III depression studies (X‑NOVA2/X‑NOVA3 in MDD; X‑CEED in bipolar depression) with X‑NOVA2 top-line readout expected H1 2027, and advancing early-stage pain programs (XEN1701 Nav1.7 and XEN1120 Kv7) with first-in-human studies expected to complete this year and plans for Phase II acute pain PoC. The company completed a ~$747.5M financing and ended Q1 with ~$1.3B cash and marketable securities, which management says funds operations into 2029 and supports commercial build and further development. Xenon will pursue global regulatory/clinical alignment (including Japan) but expects to seek ex‑U.S. partners for commercialization.